Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | AB248 |
| Trade Name | |
| Synonyms | AB-248|AB 248 |
| Drug Descriptions |
AB248 is a fusion protein comprised of an anti-CD8 antibody fused to an IL-2 mutein, which preferentially targets CD8+ T-lymphocytes, potentially resulting in increased antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 3518). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| AB248 | AB248 | 0 | 1 |
| AB248 + AZD2936 | AB248 AZD2936 | 0 | 1 |
| AB248 + Pembrolizumab | AB248 Pembrolizumab | 0 | 1 |
| AB248 + Tarlatamab | AB248 Tarlatamab | 0 | 1 |